EGFR mutation-positive inoperable or reccrent NSCLC

Clinical trials for EGFR mutation-positive inoperable or reccrent NSCLC explained in plain language.

Never miss a new study

Get alerted when new EGFR mutation-positive inoperable or reccrent NSCLC trials appear

Sign up with your email to follow new studies for EGFR mutation-positive inoperable or reccrent NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

New lung cancer drug shows promise in japanese study

Disease control Completed

This study tested the safety and effectiveness of Vizimpro (dacomitinib) in 40 Japanese patients with EGFR-mutated non-small cell lung cancer that could not be surgically removed or had returned. Researchers tracked side effects, especially interstitial lung disease, and measured…

Matched conditions: EGFR MUTATION-POSITIVE INOPERABLE OR RECCRENT NSCLC

Sponsor: Pfizer • Aim: Disease control

Last updated Jun 27, 2026 13:06 UTC

EGFR mutation-positive inoperable or reccrent NSCLC

Get alerted when new EGFR mutation-positive inoperable or reccrent NSCLC trials appear

New lung cancer drug shows promise in japanese study